Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL231 inhalation solution crossover study in COPD
ChiCTR2300068316Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of HL231 Solution for Inhalation and indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Lung function test, Safety assessment and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
HL231 Solution for Inhalationindacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2300068316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068316.